Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Cell-based Assay Market - Global Forecast 2026-2032 | AI, 3D Models, and Automation Drive a USD 42.39 Billion Opportunity by 2032

globenewswire.com
AGNC Agilent Technologies is mentioned as a company within the cell-based assay market. The article does not provide specific sentiment towards the company, but its inclusion suggests it is a player in this growing market. BDX Becton, Dickinson and Company is listed as a company in the cell-based assay market. The article does not offer specific sentiment, but its presence indicates participation in this sector. BIIB Bio-Rad Laboratories is mentioned as a company within the cell-based assay market. The article does not provide specific sentiment, but its inclusion suggests it is a player in this growing market. CDNS Charles River Laboratories is listed as a company in the cell-based assay market. The article does not offer specific sentiment, but its presence indicates participation in this sector. CNX Corning Incorporated is mentioned as a company within the cell-based assay market. The article does not provide specific sentiment, but its inclusion suggests it is a player in this growing market. DHR Danaher Corporation is listed as a company in the cell-based assay market. The article does not offer specific sentiment, but its presence indicates participation in this sector. GEHC GE HealthCare Technologies Inc. is mentioned as a company within the cell-based assay market. The article does not provide specific sentiment, but its inclusion suggests it is a player in this growing market. ILMN Illumina, Inc. is listed as a company in the cell-based assay market. The article does not offer specific sentiment, but its presence indicates participation in this sector. LMT Lockheed Martin Corporation is mentioned as a company within the cell-based assay market. The article does not provide specific sentiment, but its inclusion suggests it is a player in this growing market. MDLZ Mondelez International, Inc. is listed as a company in the cell-based assay market. The article does not offer specific sentiment, but its presence indicates participation in this sector. NOC Northrop Grumman Corporation is listed as a company in the cell-based assay market. The article does not offer specific sentiment, but its presence indicates participation in this sector. ORCL Oracle Corporation is mentioned as a company within the cell-based assay market. The article does not provide specific sentiment, but its inclusion suggests it is a player in this growing market. QGEN Qiagen N.V. is mentioned as a company within the cell-based assay market. The article does not provide specific sentiment, but its inclusion suggests it is a player in this growing market. TMO Thermo Fisher Scientific Inc. is listed as a company in the cell-based assay market. The article does not offer specific sentiment, but its presence indicates participation in this sector.

Cell-based Assay Market - Global Forecast 2026-2032 | AI, 3D Models, and Automation Drive a USD 42.39 Billion Opportunity by 2032 Dublin, Oct. 19, 2026 (GLOBE NEWSWIRE) -- "Cell-based Assay Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.

This market research report analyzes the global cell-based assay market, which is projected to reach USD 26.00 billion in 2026 and grow at a CAGR of 8.35% to USD 42.39 billion by 2032. It examines the technologies, applications, regional dynamics, and competitive priorities shaping demand as life sciences organizations adopt more predictive, human-relevant biological models.

Market Overview

Cell-based assays are advancing from endpoint testing toward sophisticated applications in drug discovery, toxicology, oncology, immunology, neuroscience, infectious disease research, and regenerative medicine. Growth is supported by sustained biopharmaceutical R&D, high-throughput screening, and increasing use of primary cells, stem cells, organoids, co-culture systems, and engineered cell models.

Validated assays measure viability, proliferation, cytotoxicity, receptor binding, signaling, apoptosis, immune response, phenotypic change, and mechanisms of action. As regulators and sponsors prioritize translational evidence and reduced reliance on animal testing, reproducibility, sensitivity, specificity, and data integrity remain critical purchasing considerations.

Transformative Technology Shifts

These insights support strategic planning by clarifying which platforms are gaining commercial traction and where investments can strengthen workflow efficiency and competitive differentiation.

Artificial Intelligence in Cell-Based Assays

Artificial intelligence is accelerating assay development through automated analysis of morphology, confluence, subcellular localization, cellular heterogeneity, and complex phenotypes. Machine learning also supports assay optimization, hit selection, toxicity prediction, dose-response interpretation, quality control, and anomaly detection.

Leading implementations combine curated biological data with validated algorithms, audit trails, cybersecurity, and governance aligned with GxP, 21 CFR Part 11 expectations, ALCOA+ principles, and reproducible data-management practices.

Regional and Economic Group Insights

ASEAN is strengthening biomedical manufacturing and CRO services, led by Singapore as a translational life sciences hub. GCC investment centers on genomics and precision medicine, while BRICS markets offer scale through growing biopharma capacity. G7 markets anchor innovation and premium instrumentation, and NATO members increasingly prioritize biosecurity and life science supply-chain resilience.

Country-level comparisons enable market entry teams to assess innovation capacity, regulatory readiness, partnership potential, and infrastructure risk across established and emerging markets.

Strategic Priorities for Industry Participants

Applying these priorities can reduce development risk, improve reproducibility, and reveal opportunities for scalable product development and geographic expansion.

Key Takeaways from This Report

Key Attributes:

Key Topics Covered:

1. Preface

1.1. Objectives of the Study

1.2. Market Definition

1.3. Market Segmentation & Coverage

1.4. Years Considered for the Study

1.5. Currency Considered for the Study

1.6. Language Considered for the Study

1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction

2.2. Research Design

2.2.1. Primary Research

2.2.2. Secondary Research

2.3. Research Framework

2.3.1. Qualitative Analysis

2.3.2. Quantitative Analysis

2.4. Market Size Estimation

2.4.1. Top-Down Approach

2.4.2. Bottom-Up Approach

2.5. Data Triangulation

2.6. Research Outcomes

2.7. Research Assumptions

2.8. Research Limitations

3. Executive Summary

3.1. Introduction

3.2. CXO Perspective

3.3. New Revenue Opportunities

3.4. Next-Generation Business Models

3.5. Industry Roadmap

4. Market Overview

4.1. Introduction

4.2. Industry Ecosystem & Value Chain Analysis

4.2.1. Supply-Side Analysis

4.2.2. Demand-Side Analysis

4.2.3. Stakeholder Analysis

4.3. Market Dynamics

4.3.1. Key Drivers

4.3.2. Key Restraints

4.3.3. Key Opportunities

4.3.4. Key Challenges

4.4. Porter's Five Forces Analysis

4.5. PESTLE Analysis

4.6. Market Outlook

4.6.1. Near-Term Market Outlook (0-2 Years)

4.6.2. Medium-Term Market Outlook (3-5 Years)

4.6.3. Long-Term Market Outlook (5-10 Years)

4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective

5.2. Consumer Experience Benchmarking

5.3. Opportunity Mapping

5.4. Distribution Channel Analysis

5.5. Pricing Trend Analysis

5.6. Regulatory Compliance & Standards Framework

5.7. ESG & Sustainability Analysis

5.8. Disruption & Risk Scenarios

5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cell-based Assay Market, by Product

7.1. Introduction

7.2. Instruments

7.2.1. Imaging Systems

7.2.2. Microplate Readers

7.3. Kits

7.3.1. Proliferation Kits

7.3.2. Viability Kits

7.4. Reagents

7.4.1. Antibodies

7.4.2. Dyes

7.4.3. Enzymes

7.5. Services

7.5.1. Contract Screening Services

7.5.2. Custom Assay Development

7.6. Software

7.6.1. Analysis Software

7.6.2. Data Management Software

8. Cell-based Assay Market, by Technology

8.1. Introduction

8.2. Fluorescence-Based Detection

8.3. High Throughput Screening

8.4. Impedance-Based Detection

8.5. Label-Free Detection

8.6. Luminescence-Based Detection

9. Cell-based Assay Market, by Assay Type

9.1. Introduction

9.2. Cytotoxicity Assay

9.2.1. LDH Assay

9.2.2. MTS Assay

9.2.3. PI Assay

9.3. Fluorescence Polarization Assay

9.3.1. FP Binding Assay

9.3.2. FP Displacement Assay

9.4. Proliferation Assay

9.4.1. BrdU Assay

9.4.2. CFSE Assay

9.4.3. EdU Assay

9.5. Reporter Gene Assay

9.5.1. GFP Assay

9.5.2. Luciferase Assay

9.5.3. ?-Galactosidase Assay

9.6. Viability Assay

9.6.1. ATP Assay

9.6.2. MTT Assay

9.6.3. Resazurin Assay

10. Cell-based Assay Market, by Application

10.1. Introduction

10.2. Cell Biology Studies

10.3. Disease Research

10.4. Drug Screening

10.5. Personalized Medicine

10.6. Toxicity Testing

11. Cell-based Assay Market, by End User

11.1. Introduction

11.2. Academic And Research Institutes

11.3. Clinical Testing Labs

11.4. Contract Research Organizations

11.5. Pharmaceutical And Biotech Companies

12. Cell-based Assay Market, by Region

12.1. Introduction

12.2. Asia-Pacific

12.3. North America

12.4. Latin America

12.5. Europe

12.6. Middle East

12.7. Africa

13. Cell-based Assay Market, by Group

13.1. Introduction

13.2. ASEAN

13.3. GCC

13.4. European Union

13.5. BRICS

13.6. G7

13.7. NATO

14. Cell-based Assay Market, by Country

14.1. Introduction

14.2. United States

14.3. Canada

14.4. Mexico

14.5. Brazil

14.6. United Kingdom

14.7. Germany

14.8. France

14.9. Russia

14.10. Italy

14.11. Spain

14.12. China

14.13. India

14.14. Japan

14.15. Australia

14.16. South Korea

15. Competitive Landscape

15.1. Market Share Analysis, 2025

15.2. Market Concentration Analysis, 2025

15.2.1. Concentration Ratio (CR)

15.2.2. Herfindahl Hirschman Index (HHI)

15.3. Recent Developments & Impact Analysis, 2025

15.4. Product Portfolio Analysis, 2025

15.5. Benchmarking Analysis, 2025

16. Company Profiles

16.1. Abcam plc

16.2. Abzena Ltd.

16.3. Agilent Technologies, Inc.

16.4. Becton, Dickinson and Company

16.5. Bio-Rad Laboratories, Inc.

16.6. BioIVT LLC

16.7. BioTek Instruments, Inc.

16.8. BioVision, Inc.

16.9. BMG LABTECH GmbH

16.10. Cell Signaling Technology, Inc.

16.11. Charles River Laboratories International, Inc.

16.12. Cisbio Bioassays SAS

16.13. Corning Incorporated

16.14. Danaher Corporation

16.15. Enzo Life Sciences, Inc.

16.16. Eurofins Scientific SE

16.17. Evotec SE

16.18. F. Hoffmann-La Roche Ltd.

16.19. Fujifilm Cellular Dynamics, Inc.

16.20. GE HealthCare Technologies Inc.

16.21. Lonza Group AG

16.22. Merck KGaA

16.23. Miltenyi Biotec B.V. & Co. KG

16.24. Molecular Devices, LLC

16.25. NanoString Technologies, Inc.

16.26. OriGene Technologies, Inc.

16.27. PerkinElmer, Inc.

16.28. Promega Corporation

16.29. Qiagen N.V.

16.30. Sartorius AG

16.31. STEMCELL Technologies Inc.

16.32. Takara Bio Inc.

16.33. Tecan Group Ltd.

16.34. Thermo Fisher Scientific Inc.

17. Key Experts

List of Figures [21]

List of Tables [375]

For more information about this report visit https://www.researchandmarkets.com/r/uddrvg

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.